CN104159601B - 弯曲杆菌属免疫原性组合物及其用途 - Google Patents

弯曲杆菌属免疫原性组合物及其用途 Download PDF

Info

Publication number
CN104159601B
CN104159601B CN201380012681.7A CN201380012681A CN104159601B CN 104159601 B CN104159601 B CN 104159601B CN 201380012681 A CN201380012681 A CN 201380012681A CN 104159601 B CN104159601 B CN 104159601B
Authority
CN
China
Prior art keywords
protein
seq
immunogenic composition
campylobacter
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380012681.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104159601A (zh
Inventor
L·A·琼斯
B·劳
A·阿姆斯特朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona filed Critical University of Arizona
Publication of CN104159601A publication Critical patent/CN104159601A/zh
Application granted granted Critical
Publication of CN104159601B publication Critical patent/CN104159601B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380012681.7A 2012-02-01 2013-02-01 弯曲杆菌属免疫原性组合物及其用途 Active CN104159601B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261632888P 2012-02-01 2012-02-01
US61/632,888 2012-02-01
US201261689078P 2012-05-29 2012-05-29
US61/689,078 2012-05-29
PCT/US2013/024332 WO2013116639A1 (en) 2012-02-01 2013-02-01 Campylobacter immunogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN104159601A CN104159601A (zh) 2014-11-19
CN104159601B true CN104159601B (zh) 2017-05-24

Family

ID=47682080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380012681.7A Active CN104159601B (zh) 2012-02-01 2013-02-01 弯曲杆菌属免疫原性组合物及其用途

Country Status (5)

Country Link
US (4) US9328148B2 (enExample)
EP (1) EP2809347A1 (enExample)
CN (1) CN104159601B (enExample)
BR (1) BR112014018732A8 (enExample)
WO (1) WO2013116639A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2766388A1 (en) * 2011-10-12 2014-08-20 Møller, Niels Iversen Peptides derived from campylobacter jejuni and their use in vaccination
CN104159601B (zh) * 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US20150044698A1 (en) * 2013-08-06 2015-02-12 Techlab, Inc. Outer membrane protein 18 as a diagnostic marker for campylobacter
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3573654A4 (en) * 2017-01-27 2020-11-25 University of Florida Research Foundation, Incorporated FOOD SAFETY VACCINE TO CONTROL SALMONELLA ENTERICA AND REDUCE CAMPYLOBACTER IN POULTRY
CN110041109A (zh) * 2019-04-22 2019-07-23 刘坚 一种猪粪源生物肥的制备方法
CN111041017B (zh) * 2019-12-31 2020-10-16 潍坊麦卡阿吉生物科技有限公司 一种壳聚糖酶突变体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049641A2 (en) * 2003-11-21 2005-06-02 Ace Biosciences A/S Surface-located campylobacter jejuni polypeptides
WO2008008092A2 (en) * 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter pilus protein, compositions and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
US20010038844A1 (en) * 1998-05-04 2001-11-08 Irving Nachamkin Methods and vaccines for protection against campylobacter infections
WO2003096812A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
CN104159601B (zh) * 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049641A2 (en) * 2003-11-21 2005-06-02 Ace Biosciences A/S Surface-located campylobacter jejuni polypeptides
WO2008008092A2 (en) * 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter pilus protein, compositions and methods

Also Published As

Publication number Publication date
CN104159601A (zh) 2014-11-19
US9328148B2 (en) 2016-05-03
BR112014018732A8 (pt) 2017-07-11
EP2809347A1 (en) 2014-12-10
BR112014018732A2 (enExample) 2017-06-20
US11203618B2 (en) 2021-12-21
US10683330B2 (en) 2020-06-16
US10030054B2 (en) 2018-07-24
US20200317737A1 (en) 2020-10-08
US20150030624A1 (en) 2015-01-29
US20160184422A1 (en) 2016-06-30
WO2013116639A1 (en) 2013-08-08
US20190031725A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CN104159601B (zh) 弯曲杆菌属免疫原性组合物及其用途
EP3122374B1 (en) Immunological compositions containing attenuated histophilus somni
EA036764B1 (ru) Ослабленный штамм streptococcus suis, индуцирующий иммунный ответ у свиней, и его применение
US20200390883A1 (en) Novel adjuvant for animal and human vaccines
Colavecchio et al. Phage therapy approaches to reducing pathogen persistence and transmission in animal production environments: Opportunities and challenges
US9358283B2 (en) Diatom-based vaccines
US20190322707A1 (en) Mutated Salmonella Enterica
AU2017202354B2 (en) Attenuated Mannheimia haemolytica vaccines and methods of making and use
CN107158371A (zh) 一种基因工程亚单位二联口服疫苗
Briggs et al. Bivalent vaccination against pneumonic pasteurellosis in domestic sheep and goats with modified-live in-frame lktA deletion mutants of Mannheimia haemolytica
JP2007504155A (ja) 弱毒細菌生ワクチン
HK1236291A1 (en) Immunological compositions containing attenuated histophilus somni
HK1209317B (en) Attenuated mannheimia haemolytica vaccines and methods of making and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant